Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

Human growth hormone can treat cystic fibrosis symptoms

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by HHS' Agency for Healthcare Research and Quality (AHRQ).

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Chronic infection with S. maltophilia bacterium may impact cystic fibrosis progression: Study

Exacerbations in cystic fibrosis (CF) may be linked to chronic infection with a bacterium called Stenotrophomonas maltophilia, which was previously thought to simply colonize the CF lung. The finding that chronic infection with S. maltophilia is independently linked with an increased risk of exacerbations gives clinicians and researchers a new potential measure of the health status of CF patients, as well as a new potential target in fighting their disease.

4 Oct 2010

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

The Pulmonary Fibrosis Foundation (PFF) today announced its October schedule of fundraising events as part of its ongoing national campaign to raise funds for pulmonary fibrosis (PF) research, while supporting the PFF's patient education and advocacy efforts throughout the country. The PFF has seen continued expansion of its public support throughout the United States, with more than 40 local and regional fundraisers contributing greatly to the Foundation's total of more than $800,000 in gifts this year.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

University of Missouri researchers believe they have found a critical piece of the puzzle for the treatment of Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world. Nearly one in 6,000 births has SMA, and it is estimated that nearly one in 30 to 40 people have the trait that leads to SMA.

29 Sep 2010

Researchers identify biomarkers for mesothelioma and pancreatic cancer

Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer, pancreatic and mesothelioma.

29 Sep 2010

GenMark’s eSensor technology selected for Warfarin clinical study

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, announced today that their eSensor Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study the WARFARIN Trial.

28 Sep 2010

Amira submits IND application for AM152 antagonist

Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

28 Sep 2010

Vertex exercises option to purchase additional $25 million notes

Vertex Pharmaceuticals Incorporated today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate principal amount of notes. The exercise of the option brings the total aggregate principal amount of notes sold in the offering to $400 million

27 Sep 2010

Legislation to help speed research for cystic fibrosis and other rare diseases

Today the U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.

24 Sep 2010

New federal funds to create first national patient registry for pulmonary fibrosis

During the 8th annual National Pulmonary Fibrosis (PF) Awareness Week, Sept. 11 to 18, the Coalition for Pulmonary Fibrosis (CPF) met with over 45 legislators, both Representatives and Senators, and as of this date there are 139 House co-sponsors for the Pulmonary Fibrosis Research Enhancement Act (PFREA) to fund research on this deadly disease.

24 Sep 2010

Aradigm Corporation receives $891,000 to purchase common stock shares

Aradigm Corporation today announced that it has received proceeds of approximately $891,000 from the exercise of all of the warrants to purchase an aggregate of 7,527,214 shares of the Company's common stock that were issued in the private placement that closed on June 21, 2010.

23 Sep 2010

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.

23 Sep 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal.

22 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

Fibrosis News and Research

Further Reading

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Amgen announces PRIME '203' and '181' Phase 3 trial results

Human growth hormone can treat cystic fibrosis symptoms

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Chronic infection with S. maltophilia bacterium may impact cystic fibrosis progression: Study

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

Researchers identify biomarkers for mesothelioma and pancreatic cancer

GenMark’s eSensor technology selected for Warfarin clinical study

Amira submits IND application for AM152 antagonist

Vertex exercises option to purchase additional $25 million notes

Legislation to help speed research for cystic fibrosis and other rare diseases

New federal funds to create first national patient registry for pulmonary fibrosis

Aradigm Corporation receives $891,000 to purchase common stock shares

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

ProtAffin presents impressive efficacy data for PA401 in COPD

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News